The funding, approximately 1.2397 billion yuan, will be used for AsymBio's principal business operations, further expansion of its manufacturing capacity, and scaling of client programs. Following the transaction, Asymchem Group's shareholding in its subsidiary AsymBio is set to rise to 83.4965%.